Vivoryon Therapeutics N.V.
VVY | AS
Overview
Corporate Details
- ISIN(s):
- NL00150002Q7
- LEI:
- 3912004AMB0KGZXZYJ15
- Country:
- Germany
- Address:
- Weinbergweg 22, 06120 Halle (Saale)
- Website:
- https://www.vivoryon.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
We are focused on developing innovative small molecule-based medicines. Driven by our passion for ground-breaking science and innovation, we strive to change the lives of patients in need suffering from severe diseases. We build on our in-depth expertise in understanding post-translational modifications to develop medicines that modulate the activity and stability of proteins which are altered in disease settings
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for Vivoryon Therapeutics N.V..
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-06-27 07:36 |
Report Publication Announcement
Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conferences
|
English | 649.6 KB | |
| 2025-06-17 07:52 |
Earnings Release
Vivoryon Therapeutics N.V. Q1 2025 Financial Results and Operational Progress
|
English | 716.2 KB | |
| 2025-06-11 07:44 |
Report Publication Announcement
Vivoryon Therapeutics N.V. to Report Q1 2025 Financial Results and Operational …
|
English | 650.9 KB | |
| 2025-06-06 10:30 |
Regulatory News Service
Vivoryon Therapeutics N.V. Presents Meta-analysis Data of VIVIAD and VIVA-MIND …
|
English | 654.5 KB | |
| 2025-06-05 14:00 |
Regulatory News Service
ViGeneron Rebrands as VeonGen Therapeutics and Announces FDA Rare Pediatric Dis…
|
English | 8.8 KB | |
| 2025-05-27 07:44 |
Regulatory News Service
Vivoryon Therapeutics N.V. Expands Intellectual Property Portfolio with New U.S…
|
English | 686.4 KB | |
| 2025-04-29 07:02 |
Annual Report
Vivoryon Therapeutics N.V., Jaarlijkse financiële verslaggeving
|
English | 10.7 MB | |
| 2025-04-25 07:42 |
Capital/Financing Update
Vivoryon Therapeutics N.V. Signs Financing Agreement for up to EUR 15 Million
|
English | 656.2 KB | |
| 2025-02-11 18:12 |
Report Publication Announcement
Vivoryon Therapeutics N.V. to Host Virtual R&D Update with KOL Speakers on Febr…
|
English | 629.7 KB | |
| 2024-12-10 07:49 |
Earnings Release
Vivoryon Therapeutics N.V. Reports Q3 2024 Results and Highlights Progress on V…
|
English | 674.7 KB | |
| 2024-11-20 17:07 |
Earnings Release
Probiodrug announces encouraging results of the Phase 2a SAPHIR Study
|
English | 2.0 MB | |
| 2024-10-28 07:39 |
Earnings Release
Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of Varoglutam…
|
English | 722.2 KB | |
| 2024-10-11 16:18 |
Regulatory News Service
Vivoryon Therapeutics N.V. Announces Late-breaking Oral Presentation at the Ame…
|
English | 222.8 KB | |
| 2024-10-01 07:40 |
Regulatory News Service
Vivoryon Therapeutics N.V. Shares Highlights from Virtual Kidney Disease KOL Ev…
|
English | 210.7 KB | |
| 2024-09-12 10:36 |
Earnings Release
Vivoryon Therapeutics N.V. Reports H1 2024 Progress Marked by Compelling Kidney…
|
English | 803.6 KB |
Automate Your Workflow. Get a real-time feed of all Vivoryon Therapeutics N.V. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Vivoryon Therapeutics N.V. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2022-04-01 | E. Platzer | Executive member | Buy | 123,809 | 1,299,994.50 EUR |
| 2022-04-01 | U. Dauer | Executive member | Buy | 4,761 | 49,990.50 EUR |
| 2020-12-02 | D.J. von der Osten | Executive member | Buy | 20,000 | 112,400.00 EUR |
| 2020-11-30 | M. Schaeffer | Executive member | Other | 3,867 | N/A |
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
Nanexa AB | Sweden | NANEXA | |
|
Nanobiotix | France | NANO | |
|
Nanoform Finland OYJ | Finland | NANOFH | |
|
NanoGroup S.A. | Poland | NNG | |
|
Nattaro Labs AB | Sweden | NATTA | |
|
Neovacs | France | ALNEV | |
|
Newron Pharmaceuticals S.p.A. | Italy | NWRN | |
|
NextCell Pharma AB | Sweden | NXTCL | |
|
NextFerm Technologies Ltd. | Israel | NXFR | |
|
NFL Biosciences | France | ALNFL |